Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 2Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Lymphoma, Follicular 10Lymphoma 9Lymphoma, Mantle-Cell 8Lymphoma, Large B-Cell, Diffuse 6Lymphoma, B-Cell, Marginal Zone 5Leukemia, Lymphocytic, Chronic, B-Cell 5Lymphoma, B-Cell 4Recurrence 3Lymphoma, Non-Hodgkin 3Waldenstrom Macroglobulinemia 2Neoplasms 2Lymphoma, T-Cell, Peripheral 2Hodgkin Disease 2Proteostasis Deficiencies 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Lymphoma, T-Cell 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Immunoglobulin Light-chain Amyloidosis 1Immunoblastic Lymphadenopathy 1Hematopoietic and Lymphoid System Neoplasm 1Hematologic Neoplasms 1Fallopian Tube Neoplasms 1Central Nervous System Neoplasms 1Advanced Solid Tumor 1

Interventions

Bevacizumab 40Paclitaxel 35Carboplatin 28pembrolizumab 21Cyclophosphamide 15Specimen Handling 14Cisplatin 13olaparib 11Blood Specimen Collection 11niraparib 10fludarabine 10Magnetic Resonance Spectroscopy 9Drug Therapy 9liposomal doxorubicin 8Topotecan 8Taxes 8Gemcitabine 8Biopsy 8Fulvestrant 7Doxorubicin 6cemiplimab 5abemaciclib 5Surveys and Questionnaires 5Standard of Care 5Injections 5Fluorouracil 5Cytoreduction Surgical Procedures 5trastuzumab deruxtecan 4mirvetuximab soravtansine 4aldesleukin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Ovarian Neoplasms × Bendamustine Hydrochloride × Clear all
NCT06483048 2026-03-16

MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer

Mayo Clinic

Phase 1 Recruiting
12 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡